Junction opener enables CAR T cell treatment of solid tumors
Physical barriers presented by solid tumors limit CAR T cell efficacy. Thus, technologies to increase CAR T cell access to solid tumors could have massive implications in advancing CAR T cell therapies. Here we demonstrate that treatment of solid tumor-bearing mice with our Junction Opener technology and CAR T cells enhances tumor control - potentially enabling CAR T cell immunotherapy for solid tumors.
Authors
- André Lieber (ORCID: https://orcid.org/0000-0001-6742-6266)
- Malcolm S. Duthie (ORCID: https://orcid.org/0000-0002-8515-5516)
- Darrick Carter (ORCID: https://orcid.org/0000-0001-5901-3402)
- Nicholas A. Korjeff
- Shibbu Sharma
- Steven G. Reed (ORCID: https://orcid.org/0000-0001-8787-5843)
- J. A. Kim (ORCID: https://orcid.org/0009-0005-3985-8164)
- Eréne C. Niemi
- Kaman Kim
- Carrie Novák
- Steven J. Reed
Institutions
- Astellas Pharma (Japan) (JP)
- University of Washington Medical Center (US)
- TRIA Bioscience (United States) (US)
- PAI Life Sciences (United States) (US)
- Health Decision Technologies (United States) (US)
Publication Details
- Journal
- Scientific Reports
- Published
- 2026-03-07
- DOI
- https://doi.org/10.1038/s41598-026-43093-8
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00